Chemical grammar of accumulation in drug resistant acinetobacter baumannii with subcellular resolution - multidrug-resistant (MDR) project summary acinetobacter baumannii (a. Baumannii) is…

Active Project Grant Awarded Last action

Award ID
R01AI191591
Recipient
Awarding agency
Obligated
$2,386,383

Award facts

Assistance listing
93.855 Allergy and Infectious Diseases Research
Completion date 24% complete
Place of performance
Charlottesville, VA 22904, USA

Award details come from USAspending.gov.

Description

Chemical grammar of accumulation in drug resistant acinetobacter baumannii with subcellular resolution - multidrug-resistant (MDR) project summary acinetobacter baumannii (a. Baumannii) is recognized as one of the most urgent global health threats due to its high resistance to nearly all available antibiotics. The rising prevalence of infections caused by this pathogen severely limits treatment options and poses a significant challenge to modern healthcare systems. The primary obstacle in treating a. Baumannii infections lies in the bacterium's unique outer membrane, which acts as a formidable barrier, preventing many antibiotics from reaching their intracellular targets. Despite the critical need for new antibiotics and adjuvants that can overcome this barrier, our understanding of the molecular rules that govern antibiotic accumulation into a. Baumannii remains limited. This project aims to address this GAP by developing and applying innovative high-throughput screening platforms designed to measure the accumulation of small molecules in a. Baumannii with subcellular resolution. Our approach leverages two novel platforms: PAC-man (peptidoglycan accessibility click-mediated assessment) and CAC-man (cytoplasmic accessibility click-mediated assessment). These platforms will enable the rapid and detailed analysis of a large library of molecules across multiple a. Baumannii strains, including drug-resistant variants. The data generated will be used to identify the chemical properties that facilitate molecular entry and accumulation within these bacterial cells. Additionally, we will conduct a large-scale screen to discover new outer membrane disruptors that can synergize with existing antibiotics, enhancing their efficacy against MDR a. Baumannii. By integrating these findings with advanced machine learning algorithms, we aim to establish a comprehensive framework for predicting molecular permeability in a. Baumannii. The results of this research will provide critical insights into the development of next-generation antibiotics and adjuvants, addressing a pressing need in the fight against antibiotic resistance and improving outcomes for patients suffering from these difficult-to-treat infections.

Transactions

Action Obligated Date
Amendment $1,184,667
Original award $1,201,716

Subawards

Subrecipient Amount Awarded
University Of Massachusetts Sloan Siegrist, Ph.D., co-I, has expertise in bacterial genetics and chemical biology. Dr. Siegrist will supervise a graduate student and a postdoc in her… $629,505
Lehigh University The subcontract at Lehigh University will cover the development of the database based on the proposed experiments of small molecule and peptide permeation… $119,215

Quick answers

Who received award R01AI191591?

R01AI191591 was awarded to Rector & Visitors Of The University Of Virginia by National Institute of Allergy and Infectious Diseases (National Institutes of Health) on August 6, 2025.

How much is award R01AI191591 worth?

$2,386,383 has been obligated on R01AI191591.

On GovTribe

See this award's full record

  • Every transaction and subaward
  • The recipient's other awards and teaming partners
  • Similar grant awards
  • Ask GovTribe AI about this award